Aura Biosciences, Inc. (NASDAQ:AURA) Insider Conor Kilroy Sells 7,162 Shares
Aura Biosciences, Inc. insider Conor Kilroy sold 7,162 shares at $5.49 each, totaling $39,319.38, reducing his ownership by 3.84%. Post-sale, he holds 179,313 shares valued at approximately $984,428.37. The stock traded down 3.1% to $5.40, with a market cap of $271.22 million. Analysts have set a consensus target price of $22.75, with a majority rating the stock as "Buy."
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the sale, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Get Aura Biosciences alerts:
Aura Biosciences Trading Down 3.1 %
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
NASDAQ:AURA traded down $0.17 during trading hours on Wednesday, hitting $5.40. The stock had a trading volume of 138,043 shares, compared to its average volume of 200,409. The business has a 50 day simple moving average of $6.85 and a two-hundred day simple moving average of $8.23. Aura Biosciences, Inc. has a 1-year low of $3.40 and a 1-year high of $12.38. The company has a market cap of $271.22 million, a PE ratio of -3.12 and a beta of 0.43.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). Research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC increased its holdings in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock worth $15,764,000 after buying an additional 112,296 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock worth $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after buying an additional 783,984 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. JMP Securities set a $19.00 target price on Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a research note on Tuesday, March 25th. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Aura Biosciences presently has a consensus rating of "Buy" and a consensus target price of $22.75.
Read Our Latest Analysis on Aura Biosciences
About Aura Biosciences
(Get Free Report)Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
- Five stocks we like better than Aura Biosciences
- Using the MarketBeat Stock Split Calculator
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Market Cap Calculator: How to Calculate Market Cap
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- What Are Trending Stocks? Trending Stocks Explained
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Aura Biosciences Right Now?
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
